- Home
- RIGL vs PEO Comparison
RIGL vs PEO Comparison
Compare RIGL & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | PEO |
|---|---|---|
| Founded | 1996 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 570.8M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | PEO |
|---|---|---|
| Price | $34.56 | $26.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.20 | N/A |
| AVG Volume (30 Days) | ★ 257.9K | 84.6K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.93% |
| EPS Growth | ★ 807.14 | N/A |
| EPS | ★ 5.38 | N/A |
| Revenue | ★ $179,278,000.00 | N/A |
| Revenue This Year | $66.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.66 | ★ N/A |
| Revenue Growth | ★ 53.38 | N/A |
| 52 Week Low | $15.50 | $18.35 |
| 52 Week High | $52.24 | $26.28 |
Technical Indicators
Market Signals| Indicator | RIGL | PEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 70.11 |
| Support Level | $33.05 | $21.03 |
| Resistance Level | $36.95 | $26.28 |
| Average True Range (ATR) | 1.46 | 0.40 |
| MACD | 0.24 | -0.05 |
| Stochastic Oscillator | 39.78 | 88.37 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.